Matthew Duncton

USPTO Granted Patents = 40 (Patent Applications = 33)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

San Francisco, CA (US) (2007 - 2011)
San Bruno, CA (US) (2012 - 2022)
Las Vegas, NV (US) (2024)

Company Filing History:

29 out of 488

Rigel Pharmaceuticals, Incorporated

patents

4 out of 10

Terran Biosciences, Inc.

Rigl Pharmaceutical, Inc.

patent

6. 1 out of 1

Deciduous Therapeutics, Inc.

patent

7. 1 out of 832,680

Other

patents

Years Active: 2007-2025

Loading Chart...

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435036 - Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine (2025-10-07),

2. 12319652 - Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine (2025-06-03),

3. 12269818 - Analogs of xanomeline (2025-04-08),

4. 12234216 - Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof (2025-02-25),

5. 12037357 - Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells (2024-07-16),

6. 11279686 - Nrf2 activating compounds and uses thereof (2022-03-22),

7. 11174246 - Direct AMPK activators (2021-11-16),

8. 11129819 - Fumarate analogs and uses thereof (2021-09-28),

9. 10941135 - Nrf2 activating compounds and uses thereof (2021-03-09),

10. 10844040 - Nrf2 activating compounds and uses thereof (2020-11-24),

11. 10792282 - Protein kinase C inhibitors and uses thereof (2020-10-06),

12. 10647697 - Nrf2 activating compounds and uses thereof (2020-05-12),

13. 10556881 - Nrf2 activating compounds and uses thereof (2020-02-11),

14. 10493066 - Fumarate analogs and uses thereof (2019-12-03),

15. 10450280 - Tetrazolones as a carboxylic acid bioisosteres (2019-10-22),

Title: Matthew Duncton: Pioneering Inventor in the Modern Era

Introduction:

Matthew Duncton, a trailblazing inventor based in San Bruno, CA, has gained widespread recognition for his relentless pursuit of innovation and his commitment to pushing the boundaries of technology. With a stellar track record of 35 patents, Duncton's contributions continue to inspire and shape the future of innovation across the globe.

Latest Patents:

Among Duncton's latest patents are groundbreaking innovations in the medical field. One such patent includes Nrf2 activating compounds that have shown promise in the treatment of autoimmune and inflammatory diseases like psoriasis and multiple sclerosis. Additionally, his direct AMPK activators have paved the way for novel pharmaceutical compositions and methods of treating diseases by activating the AMPK pathway.

Career Highlights:

Duncton has made significant contributions to the field of biotechnology through his work at companies like Rigel Pharmaceuticals, Incorporated, and Renovis, Inc. His innovative mindset and dedication to research have led to a series of breakthrough inventions that have the potential to revolutionize the healthcare industry.

Collaborations:

Throughout his career, Duncton has collaborated with esteemed professionals in the field of biotechnology. Some of his notable coworkers include Rajinder Paul Singh and Rao Kolluri, who have worked alongside Duncton to bring his visionary ideas to life.

Conclusion:

In conclusion, Matthew Duncton's innovative spirit and pioneering mindset have cemented his position as a leading inventor in the modern era. His remarkable patents and collaborations underscore his unwavering commitment to driving technological advancements and making a lasting impact on the world of innovation.

This text is generated by artificial intelligence and may not be accurate.